- Home
- NERV vs AACG Comparison
NERV vs AACG Comparison
Compare NERV & AACG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NERV | AACG |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 25.4M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | NERV | AACG |
|---|---|---|
| Price | $4.71 | $0.81 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 45.9K | 19.4K |
| Earning Date | 02-24-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $39,316,403.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.62 |
| 52 Week Low | $1.15 | $0.71 |
| 52 Week High | $12.46 | $2.58 |
Technical Indicators
Market Signals| Indicator | NERV | AACG |
|---|---|---|
| Relative Strength Index (RSI) | 67.06 | 39.45 |
| Support Level | $3.82 | $0.79 |
| Resistance Level | $4.24 | $0.82 |
| Average True Range (ATR) | 0.29 | 0.05 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 89.56 | 53.55 |
Price Performance
Historical ComparisonAbout NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About AACG ATA Creativity Global
ATA Creativity Global is an international educational services company focused on providing quality learning experiences that cultivate and enhance students' creativity. The operating segments of the company are (i) Overseas art study services (ii) Other educational services and (iii) Other services. Majority of its revenue comes from Overseas art study services.